As the nation grapples with the pandemic, new research has identified dexamethasone, a low-cost generic drug, as a promising treatment for certain COVID-19 patients. But consumers worry – will its cost remain low? Will new treatments be affordable?
Author Archive for: johanna-butler
About Johanna Butler
Johanna Butler joined NASHP’s Emerging Policy Issues team in June 2018. She is involved with several projects related to lowering the cost of health care, focusing specifically on health system costs and prescription drug prices. She has also worked on advancing evidence-based policymaking through patient-centered outcomes research. Prior to joining NASHP, Johanna was an intern in the ranking member’s health policy office of the Senate Committee on Health, Education, Labor, and Pensions. She has also worked as the Lloyd Meeds Policy Fellow at K&L Gates and interned in the White House Office of Cabinet Affairs. Johanna graduated from American University in 2018 with an interdisciplinary studies degree focused on communications, law, economics, and government, and holds a certificate in Advanced Leadership Studies from the School of Public Affairs.
Entries by Johanna Butler
COVID-19 has profoundly affected the health care landscape, raising anew concerns about the high cost of hospitalizations while simultaneously placing new burdens on those facilities and curtailing non-emergency services. Providers, unable to see patients for routine care, lost revenue and many free-standing physician practices are now at risk, and now face increasing pressure to merge […]
As states respond to the need for increased hospital bed capacity due to COVID-19, governors and legislatures in 22 states have waived certificate-of-need (CON) requirements – streamlining the process for hospitals to add bed capacity. These waivers have focused attention on decades-old CON laws and their utility in a changing health care landscape. The National […]
As coronavirus (COVID-19) hospitalizations and ICU bed demand surge across the country, 13 states have quickly acted to implement temporary, targeted suspensions of their certificate of need (CON) requirements for construction or expansion of new health-care facilities to remove regulatory barriers to address this critical health care need. CON laws are state regulatory mechanisms to […]
Absent sufficient evidence from clinical trials that proves a variety of drugs are effective against COVID-19, many states are providing guidance to limit their use and have begun monitoring them for price increases and shortages. Building on experience from states’ drug price transparency laws, policymakers now have tools to track these drug costs and identify […]
When exploring new evidence about the effectiveness of telehealth, state policymakers want to know which interventions consumers prefer and are scalable for a range of populations. In addition to working to ensure that new telehealth tools are evidence-based and effective, officials want to make sure both patients and providers are interested in utilizing them. The […]